Astellas’ Veozah Is First-In-Class Treatment For Vasomotor Symptoms
Veozah received approval from the US FDA for a common symptom of menopause, a therapeutic area that has lacked pharmaceutical advancements.
You may also be interested in...
Organon has not strayed from its women’s health path, but is entering into earlier deals and considering technologies beyond therapeutics, while advocating increased investment in the field.
Amid positive ongoing forex impact, Astellas, Shionogi and Daiichi Sankyo logged solid fiscal years and Chugai has good growth in its first quarter, although some of the majors are expecting a decline in sales as demand due to COVID-19 wanes. Even so, Shionogi logged record results on the back on government procurement of its pandemic antiviral.
The German major has pinned its early-stage research colors to the masts of oncology, cardiovascular, neurology, rare diseases and immunology, representing a shift away from rather than an abandonment of women’s health.